(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of 264.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Citius Pharmaceuticals's revenue in 2026 is $3,944,111.On average, 3 Wall Street analysts forecast CTXR's revenue for 2026 to be $1,786,891,955, with the lowest CTXR revenue forecast at $1,716,808,985, and the highest CTXR revenue forecast at $1,839,454,182. On average, 3 Wall Street analysts forecast CTXR's revenue for 2027 to be $3,281,055,491, with the lowest CTXR revenue forecast at $3,152,391,036, and the highest CTXR revenue forecast at $3,377,497,891.
In 2028, CTXR is forecast to generate $4,192,223,598 in revenue, with the lowest revenue forecast at $4,027,980,624 and the highest revenue forecast at $4,315,741,475.